4. Corcept Therapeutics Incorporated (NASDAQ:CORT)
Corcept Therapeutics Incorporated is gaining traction following strong clinical outcomes and regulatory progress. On April 10, at the Society of Gynecologic Oncology Annual Meeting, the company reported final overall survival results from its Phase 3 ROSELLA study.
The study evaluated Lifyorli in combination with nab-paclitaxel for platinum-resistant ovarian cancer. Results showed a 35% reduction in risk of death and a 30% reduction in disease progression compared to nab-paclitaxel alone.
The U.S. FDA has already approved Lifyorli for patients with platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer who have undergone prior therapies, including bevacizumab. This approval removes a major regulatory risk.
Following the approval, Wolfe Research upgraded the stock to Peerperform from Underperform, noting that a key downside risk has been eliminated. However, the firm continues to monitor the long-term durability of Corcept’s core Cushing’s disease franchise.
The company’s pipeline spans oncology, endocrinology, and metabolic disorders, providing diversification beyond its legacy business.
Click next to see the following stock...
